SEC Form 4Coverage since Jul 28, 2026
$KPTI insider trading
Over the last 12 months, Karyopharm Therapeutics insiders reported no purchases and 1 sale totaling $1K across SEC Form 4 filings.
- Bought · 12m
- — 0 events
- Sold · 12m
- $1K 1 event
- Events · 12m
- 1 Form 4 filings, grouped
- Insiders · 12m
- 1 distinct reporters
- 10b5-1 share
- 0% pre-arranged plans
Side
Price · $KPTI · 12Mvia TradingView
Top insiders · 12m
Poulton StuartEVP, Chief Development Officer1× · $1K
All insider trades
1 event
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 28, 2026 | Poulton StuartEVP, Chief Development Officer · O | ▼ Sale | 189 | $7.1 | $1K | -0.2% | — |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $KPTI feed.